Literature DB >> 9887250

Low-grade endometrial stromal sarcoma preoperative treatment with Depo-Lupron and Megace.

D R Scribner1, J L Walker.   

Abstract

A 46-year-old women presented with an inoperable low-grade endometrial stromal sarcoma. Two doses of Depo-Lupron, 7.5 mg, and Megace, 160 mg/day, were given to control uterine bleeding and shrink the tumor mass. In 9 weeks, significant reduction in the tumor occurred allowing for surgical resection. Total abdominal hysterectomy with bilateral salpingo-oophorectomy is the mainstay for primary treatment. The role of chemotherapy, radiation therapy, and hormonal therapy is poorly defined. This is a case report of neoadjuvant hormonal therapy which may improve outcomes in patients with endometrial stromal sarcomas. Additional research is needed to define the exact role of these agents. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9887250     DOI: 10.1006/gyno.1998.5174

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  11 in total

1.  Prolonged long-term survival of low-grade endometrial stromal sarcoma patients with lung metastasis following treatment with medroxyprogesterone acetate.

Authors:  Kentaro Nakayama; Masako Ishikawa; Yutaka Nagai; Nobuo Yaegashi; Yoichi Aoki; Khoji Miyazaki
Journal:  Int J Clin Oncol       Date:  2010-03-10       Impact factor: 3.402

2.  Long-term survival of patients given hormonal therapy for metastatic endometrial stromal sarcoma.

Authors:  J-P Spano; J-C Soria; M Kambouchner; S Piperno-Neuman; F Morin; J-F Morere; A Martin; J-L Breau
Journal:  Med Oncol       Date:  2003       Impact factor: 3.064

3.  Recurrent endometrial stromal sarcoma: treatment with a progestin and gonadotropin releasing hormone agonist.

Authors:  Nefertiti Chianti Dupont; Philip John Disaia
Journal:  Sarcoma       Date:  2010-06-10

4.  Expression of androgen receptors in benign and malignant endometrial stromal neoplasms.

Authors:  Farid Moinfar; Peter Regitnig; Ali Dastranj Tabrizi; Helmut Denk; Fattaneh A Tavassoli
Journal:  Virchows Arch       Date:  2004-03-06       Impact factor: 4.064

5.  Investigation of hormone receptor expression and its prognostic value in endometrial stromal sarcoma.

Authors:  Jeong-Yeol Park; Min-Hyun Baek; Yangsoon Park; Young-Tak Kim; Joo-Hyun Nam
Journal:  Virchows Arch       Date:  2018-06-04       Impact factor: 4.064

6.  Expression of oestrogen and progesterone receptors in low-grade endometrial stromal sarcomas.

Authors:  O Reich; S Regauer; W Urdl; M Lahousen; R Winter
Journal:  Br J Cancer       Date:  2000-03       Impact factor: 7.640

7.  Long-term survival in low-grade endometrial stromal sarcoma with childbirth and multidisciplinary treatment: a case report.

Authors:  Osamu Maeda; Suzuko Moritani; Shu Ichihara; Takami Inoue; Yutaka Ishihara; Shinichi Yamamoto; Makoto Ito; Yoko Matsumura; Kumiko Sugiyama; Maiko Horio; Ikuyo Kondo
Journal:  J Med Case Rep       Date:  2015-10-20

8.  Letrozole as second-line hormonal treatment for recurrent low-grade endometrial stromal sarcoma: A case report and review of the literature.

Authors:  Kohei Nakamura; Kentaro Nakayama; Masako Ishikawa; Noriyoshi Ishikawa; Hiroshi Katagiri; Atsuko Katagiri; Tomoka Ishibashi; Emi Sato; Kohji Iida; Razia Sultana; Satoru Kyo
Journal:  Oncol Lett       Date:  2016-09-26       Impact factor: 2.967

9.  Complete remission of advanced low-grade endometrial stromal sarcoma after aromatase inhibitor therapy: a case report.

Authors:  Omar F Altal; Ahmed H Al Sharie; Omar M Halalsheh; Nour Tashtush; Sarat Shaban; Mahmoud Alfaqih; Abdelwahab Aleshawi
Journal:  J Med Case Rep       Date:  2021-05-05

Review 10.  Treatment of early uterine sarcomas: disentangling adjuvant modalities.

Authors:  Flora Zagouri; Athanasios-Meletios Dimopoulos; Stelios Fotiou; Vassilios Kouloulias; Christos A Papadimitriou
Journal:  World J Surg Oncol       Date:  2009-04-08       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.